C9172 — Injection, fidanacogene elaparvovec-dzkt, per therapeutic dose
C9172 is a HCPCS Level II code for injection, fidanacogene elaparvovec-dzkt, per therapeutic dose. It belongs to the Outpatient Prospective Payment System section. It was terminated on December 31, 2024 and is not valid on new claims.
This code has been terminated
CMS terminated C9172 on December 31, 2024. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9172
- Long descriptor
- Injection, fidanacogene elaparvovec-dzkt, per therapeutic dose
- Short descriptor
- Inj, beqvez, per tx dose
- Added
- October 1, 2024
- Terminated
- December 31, 2024
- BETOS
- O1E
- Pricing indicator
- 53 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Statute.
Codes adjacent to C9172
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9172 is not quite right, the correct code is very often within a few positions of it.
- C9164Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)terminated
- C9165Injection, elranatamab-bcmm, 1 mgterminated
- C9166Injection, secukinumab, intravenous, 1 mgterminated
- C9167Injection, adamts13, recombinant-krhn, 10 iuterminated
- C9168Injection, mirikizumab-mrkz, 1 mgterminated
- C9169Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgramterminated
- C9170Injection, tarlatamab-dlle, 1 mgterminated
- C9171Injection, pegulicianine, 1 mgterminated
- C9173Injection, filgrastim-txid (nypozi), biosimilar, 1 microgramterminated
- C9174Injection, datopotamab deruxtecan-dlnk, 1 mgterminated
- C9175Injection, treosulfan, 50 mgterminated
- C9176Tc-99m from domestically produced non-heu mo-99, [minimum 50 percent], full cost recovery add-on, per study dose
- C9248Injection, clevidipine butyrate, 1 mgterminated
- C9250Human plasma fibrin sealant, vapor-heated, solvent-detergent (artiss), 2 ml
- C9254Injection, lacosamide, 1 mg
- C9257Injection, bevacizumab, 0.25 mg
Questions about C9172
What is HCPCS code C9172?
C9172 is a HCPCS Level II code for injection, fidanacogene elaparvovec-dzkt, per therapeutic dose. It sits in the Outpatient Prospective Payment System section.
Does Medicare cover C9172?
The CMS HCPCS file marks C9172 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is C9172 still valid?
No. C9172 was terminated on December 31, 2024 and should not be used on new claims.